生物活性：Fenofibrate-d4 is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Fenofibrate-d4 相关抗体:
PPAR alpha Antibody
Cytochrome C Antibody
PPAR gamma Antibody
PPAR gamma Antibody (YA122)
Cytochrome P450 17A1 Antibody
Aromatase Antibody
CYP11A1 Antibody
Cytochrome P450 1B1 Antibody (YA1836)
Adrenodoxin Antibody (YA2005)
Cytochrome P450 27A1 Antibody (YA2163)
Cytochrome P450 2C9 Antibody (YA2166)
Cytochrome P450 2E1 Antibody (YA2302)
Cytochrome P450 Reductase Antibody (YA2619)
Thromboxane A Synthase Antibody (YA2670)
Cytochrome P450 3A4 Antibody (YA3365)
HSD11B1 Antibody (YA3376)
Cytochrome P450 17A1 Antibody (YA786)
CYP2E1 Antibody
CYP1A2 Antibody
PGC1 beta Antibody (YA1411)
PLSCR3 Antibody (YA1672)
PROX1 Antibody (YA1754)
Cytochrome P450 4A Antibody (YA2087)
Cytochrome P450 24A1 Antibody (YA2121)
Cytochrome P450 26A1 Antibody (YA2259)
COX5B Antibody (YA2550)
Steroidogenic Factor 1 Antibody (YA3166)
Dynein Light Chain Tctex Type 1 Antibody (YA3263)
Cytochrome P450 2D6 Antibody (YA3384)
分子量：364.86
Formula：C20H17D4ClO4
CAS 号：1092484-57-5
非标记 CAS：49562-28-9
中文名称：非诺贝特-d4
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (527 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78(3):639-48.
 [Content Brief]
[3]. Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964(16)30448-0.
 [Content Brief]